PHILADELPHIA - (KRT) - A Bucks County, Pa.,
woman participating in human testing of an experimental
anti-depression drug killed herself at a test laboratory in
Indianapolis, Ind., police have reported.
Authorities are awaiting the outcome of toxicology tests on the
body of Traci Johnson, 19, of Bensalem, who police said hanged
herself Saturay at the Lilly Laboratory for Clinical Research. A
nurse found her dead about 8:20 p.m. in a bathroom at the
A spokeswoman for the Marion County coroner's office said it
might take up to two months for the results of toxicological
Laura Bradbard, a spokeswoman for the federal Food and Drug
Administration, said, "The agency is aware of this death and is
A Lilly spokesman, Rob Smith, said the toxicology tests "in all
likelihood" won't definitively prove whether the impact of the drug,
duloxetine, or Johnson's withdrawal from it, caused her to take her
own life. "We have not seen any sign that the drug can be linked to
any kind of suicidal behavior," he said.
Relatives of Johnson, a former Indiana Bible College student,
could not be reached yesterday.
The drug is being tested for both depression and stress urinary
Smith said final testing of duloxetine required for FDA approval
is nearing its conclusion.
He said the company would "let facts guide us," but "it appears
this is an isolated tragedy."
Johnson was among 100 healthy participants in the latest tests,
Smith said. She received $150 a day plus meals.
Johnson initially took the drug but recently was switched to a
placebo, Smith said.
Smith said there had been four suicides in the clinical trials
for duloxetine, out of 9,000 participants.
He said it was "very, very rare" for healthy participants to take
their own life.
"The deaths in the study occurred with people who actually were
depressed when they started the study."
© 2004, Philadelphia Daily News.
Visit Philadelphia Online, the World Wide Web site of the
Philadelphia Daily News, at "http://www.philly.com/"
Distributed by Knight Ridder/Tribune Information